CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The therapy from Vertex Pharmaceuticals and CRISPR Therapeutics will cost the ... was approved for use in the NHS in August to treat beta thalassemia, another rare blood disorder.